source
- Sarepta tumbles as its gene therapy sales decline furtherEven though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.BioPharma Dive · 2mo ago↗ source
- Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts WarnTimothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.onclive · 2mo ago↗ source
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 2mo ago↗ source